Combining a WT1 Vaccine (Galinpepimut-S) With Checkpoint Inhibition (Nivolumab) in Patients With WT1–Expressing Diffuse Pleural Mesothelioma: A Phase 1 Study

Introduction: WT1 often presents on the surface of diffuse pleural mesotheliomas (DPMs) and is an ideal therapeutic target. Galinpepimut-S (GPS), a tetravalent, non–human leukocyte antigen–restricted, heteroclitic WT1–specific peptide vaccine was safe and effective in early phase clinical trials and...

詳細記述

書誌詳細

出版年:	JTO Clinical and Research Reports
主要な著者:	Prashasti Agrawal, MD, Michael Offin, MD, Victoria Lai, MD, Michelle S. Ginsberg, MD, Prasad S. Adusumilli, MD, FACS, Valerie W. Rusch, MD, Jennifer L. Sauter, MD, Teresa Ho, BS, Phillip Wong, PhD, Marjorie G. Zauderer, MD
フォーマット:	論文
言語:	英語
出版事項:	Elsevier 2025-01-01
主題:	Mesothelioma Cancer vaccines Immunotherapy Phase 1
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S2666364324001267